Molecule of the Month. Varenicline tartrate.
D001552:Benzazepines / Q000737:chemistry / Q000627:therapeutic use*; D004311:Double-Blind Method; D017277:Drug Approval; D015507:Drugs, Investigational / Q000737:chemistry / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D015394:Molecular Structure; D018722:Nicotinic Agonists / Q000737:chemistry / Q000627:therapeutic use*; D011810:Quinoxalines / Q000737:chemistry / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011978:Receptors, Nicotinic / Q000502:physiology; D012907:Smoking / Q000188:drug therapy*; D016540:Smoking Cessation / Q000379:methods / Q000706:statistics & numerical data; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration; D000068580:Varenicline
D001552:Benzazepines; D015507:Drugs, Investigational; D018722:Nicotinic Agonists; D011810:Quinoxalines; D011978:Receptors, Nicotinic; C403531:nicotinic receptor alpha4beta2; D000068580:Varenicline